iCAD, Inc. (NASDAQ:ICAD) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET

Company Participants

Linnell Faber - Executive Assistant to Chief Executive Officer

Stacey Stevens - President & Chief Executive Officer

Steve Sarno - Chief Financial Officer

Conference Call Participants

Per Ostlund - Craig Hallum Capital Group

Francois Brisebois - Oppenheimer

Operator

Good afternoon ladies and gentlemen and welcome to the iCAD Incorporated Third Quarter 2022 Earnings Call. At this time all participants have been placed on a Listen Only mode and the floor will be open for questions and comments after the presentation. It is now my pleasure to turn the floor over to your host is Linnell Faber Executive Assistant to the Chief Executive Officer, and I know the floor is yours.

Linnell Faber

Thank you, operator. Good afternoon, everyone. Thank you for joining us today for iCAD third quarter 2022 earnings conference call on the call today we have Stacey Stevens, our President and Chief Executive Officer and Steve Sarno, our Interim Chief Financial Officer.

Before turning the call over to Stacy, I would like to remind everyone that we will be making forward looking statements on the call today. These forward looking statements are based on iCAD current expectation and are subject to uncertainty and changes in circumstances. Actual results may differ materially from these expectations. For a list of factors that could cause actual results to differ, please see today's press release in our filings with the US Securities and Exchange Commission. I can undertake no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call. I would also note that management will refer to certain non GAAP financial measures. Management believes that these measures provide meaningful information for investors and reflect the way they view the operating performance of the company. You can find a reconciliation of our GAAP to non GAAP measures at the end of the earnings release.

With that, I'll turn the call over to Stacy.

Stacey Stevens

Thank you, Eleanor and good afternoon, everyone. As we close out another quarter and look ahead towards 2023. I continue to be optimistic about the company and its prospects with a portfolio of market leading first unchain technologies. We are addressing significant unmet needs in global health. And I am confident that we are taking the right steps and that we are building the right team to ensure continued growth for the company and create additional shareholder value. That said, this is a transformational time for us in many ways. As we shift our business towards even more sustainable future driven models of business that are positioned to propel our company to new heights. In the last quarter, we have continued to make significant strides to ensure we meet and exceed our desired endpoints. Looking at the detection side of the business, I had breast AI suite remains the only complete AI solution for breast cancer detection, density evaluation and risk assessment solution available on the market today. And we continue to see this world leading technology as the ultimate value driver for the company with strong competitive differentiation and a superior value proposition, particularly when it comes to efficiency, performance and workflow benefits. underlying demand for our technology remained strong. But more importantly, our solutions continue to have a positive impact on patient lives. And we believe they will, over time become standard of care.